<p>Natera, Inc.（納斯達克代碼：NTRA - 獲取免費報告）內部人士 John Fesko 於 5 月 26 日（星期二）出售了 1,438 股該公司的股票。股票的平均售價為 202.84 美元，總價值為 291,683.92 美元。交易後，該內部人士直接持有 185,782 股公司股票，價值為 37,684,020.88 美元。這筆交易代表其持股比例下降了 0.77%。該出售在與 SEC 的法律文件中披露，相關信息可在 SEC 網站上查閲。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售的目的是為了覆蓋與股權獎勵歸屬相關的税款扣繳義務。</p>
<ul>
<li>3 家不為人知的醫療保健公司</li>
</ul>
<p>John Fesko 最近還進行了以下交易：</p>
<ul>
<li>5 月 1 日（星期五），John Fesko 出售了 291 股 Natera 股票。股票的平均售價為 206.16 美元，總價值為 59,992.56 美元。</li>
<li>4 月 27 日（星期一），John Fesko 出售了 1,688 股 Natera 股票。股票的平均售價為 204.10 美元，總價值為 344,520.80 美元。</li>
<li>3 月 10 日（星期二），John Fesko 出售了 707 股 Natera 股票。股票的平均售價為 204.13 美元，總價值為 144,319.91 美元。</li>
</ul>
<h2>Natera 股票表現</h2>
<p>NTRA 在星期四上漲了 10.83 美元，達到 213.94 美元。該公司交易了 1,861,579 股，相較於其平均交易量 1,650,189 股。該公司的 50 日簡單移動平均為 201.85 美元，200 日簡單移動平均為 215.63 美元。該股票的市值為 306.4 億美元，市盈率為-131.25，貝塔值為 1.57。Natera, Inc.的 12 個月低點為 131.81 美元，12 個月高點為 256.36 美元。</p>
<ul>
<li>Myriad Genetics 因遺傳癌症檢測而股價飆升</li>
</ul>
<p>Natera（納斯達克代碼：NTRA - 獲取免費報告）最後一次公佈季度財報是在 2 月 26 日（星期四）。該醫療研究公司報告每股收益為 0.35 美元，超出市場共識預期的-0.46 美元，超出幅度為 0.81 美元。該公司在本季度的收入為 6.655 億美元，而市場共識預期為 6.0068 億美元。Natera 的股本回報率為-14.74%，淨利潤率為-9.05%。在去年同期，該公司每股收益為-0.41 美元。分析師平均預計 Natera, Inc.在當前年度的每股收益為-1.49 美元。</p>
<h2>機構投資者對 Natera 的看法</h2>
<p>一些大型投資者最近調整了對該股票的持有。Reflection Asset Management 在第四季度購買了 Natera 的新股份，價值約 29,000 美元。Palladiem LLC 在第四季度購買了 Natera 的新股份，價值約 31,000 美元。Jackson Hole Trust 在第四季度將其在 Natera 的持股增加了 103.8%。Jackson Hole Trust 現在擁有 163 股該醫療研究公司的股票，價值 37,000 美元，此前在上個季度又購買了 83 股。International Assets Investment Management LLC 在第一季度將其在 Natera 的持股增加了 132.9%。International Assets Investment Management LLC 現在擁有 170 股該醫療研究公司的股票，價值 35,000 美元，此前在上個季度又購買了 97 股。最後，Kemnay Advisory Services Inc.在第四季度購買了 Natera 的新股份，價值約 39,000 美元。機構投資者持有該公司 99.90% 的股票。</p>
<h2>分析師評級變動</h2>
<p>NTRA 最近受到了一些分析師報告的關注。摩根士丹利在 3 月 3 日的報告中將 Natera 的目標股價從 265.00 美元下調至 250.00 美元，並對該公司給予 “增持” 評級。摩根大通在 5 月 8 日的報告中將 Natera 的目標股價從 260.00 美元上調至 265.00 美元，並給予該股票 “增持” 評級。富國銀行在 5 月 8 日的研究報告中將 Natera 的目標價從 215.00 美元上調至 220.00 美元，並給予該公司 “持平” 評級。Weiss Ratings 在 4 月 21 日的研究報告中重申了對 Natera 的 “賣出（d-）” 評級。最後，Robert W. Baird 在 5 月 8 日的報告中將 Natera 的目標價設定為 265.00 美元。一位分析師對該股票給予了強烈買入評級，十四位給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，共識目標價為 256.60 美元。</p>
<p><strong>查看我們對 NTRA 的最新分析</strong></p>
<h2>關於 Natera</h2>
<p>（獲取免費報告）</p>
<p>Natera 是一家全球診斷公司，開發和商業化無細胞 DNA 及其他基因檢測技術用於臨牀應用。該公司專注於三個主要領域：生殖健康（包括無創產前檢測和攜帶者篩查）、腫瘤學（用於最小殘留病和復發監測的腫瘤信息檢測）以及器官移植（用於檢測移植物損傷的無細胞 DNA 檢測）。Natera 結合實驗室檢測、專有生物信息學和臨牀報告，為臨牀醫生和患者提供個性化的基因信息。</p>
<p>主要產品包括 Panorama，一種無創產前檢測，用於篩查胎兒染色體異常和特定單基因疾病；Horizon 攜帶者篩查，用於遺傳疾病；Signatera，一種個性化的腫瘤信息檢測，用於檢測最小殘留病和監測癌症患者的治療反應；以及 Prospera，一種供體來源的無細胞 DNA 檢測，用於評估器官排斥的風險。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 Natera 更好</li>
<li>3 只因美光價格上漲而上漲的股票：實質還是炒作？</li>
<li>Snowflake 及其 AI 飛輪的滾雪球效應</li>
<li>AI 的最大瓶頸可能使這兩隻股票飆升</li>
<li>這三隻被打壓的股票剛剛看到 2500 萬美元的內部購買</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Natera 嗎？</h2>
<p>在考慮 Natera 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Natera 並不在名單上。</p>
<p>雖然 Natera 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

NTRA

<p>Natera, Inc.（納斯達克代碼：NTRA）的內部人士 John Fesko 出售了 1,438 股，平均價格為 202.84 美元，總計 291,683.92 美元。交易後，他持有 185,782 股，價值約為 3,768 萬美元，持股比例減少了 0.77%。此次出售是在一個 10b5-1 交易計劃下進行的，以滿足税務義務。Natera 的股票最近交易價格為 213.94 美元，市值為 306.4 億美元</p>

<p>Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 1,438 shares of the firm's stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $202.84, for a total value of $291,683.92. Following the transaction, the insider directly owned 185,782 shares in the company, valued at $37,684,020.88. This trade represents a 0.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.</p>
<div class="lb-trans"><p>Natera, Inc.（納斯達克代碼：NTRA - 獲取免費報告）內部人士 John Fesko 於 5 月 26 日（星期二）出售了 1,438 股該公司的股票。股票的平均售價為 202.84 美元，總價值為 291,683.92 美元。交易後，該內部人士直接持有 185,782 股公司股票，價值為 37,684,020.88 美元。這筆交易代表其持股比例下降了 0.77%。該出售在與 SEC 的法律文件中披露，相關信息可在 SEC 網站上查閲。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售的目的是為了覆蓋與股權獎勵歸屬相關的税款扣繳義務。</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不為人知的醫療保健公司</li>
</ul>
</div><p>John Fesko also recently made the following trade(s):</p>
<div class="lb-trans"><p>John Fesko 最近還進行了以下交易：</p>
</div><ul>
<li>On Friday, May 1st, John Fesko sold 291 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $59,992.56.</li>
<li>On Monday, April 27th, John Fesko sold 1,688 shares of Natera stock. The shares were sold at an average price of $204.10, for a total value of $344,520.80.</li>
<li>On Tuesday, March 10th, John Fesko sold 707 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $144,319.91.</li>
</ul>
<div class="lb-trans"><ul>
<li>5 月 1 日（星期五），John Fesko 出售了 291 股 Natera 股票。股票的平均售價為 206.16 美元，總價值為 59,992.56 美元。</li>
<li>4 月 27 日（星期一），John Fesko 出售了 1,688 股 Natera 股票。股票的平均售價為 204.10 美元，總價值為 344,520.80 美元。</li>
<li>3 月 10 日（星期二），John Fesko 出售了 707 股 Natera 股票。股票的平均售價為 204.13 美元，總價值為 144,319.91 美元。</li>
</ul>
</div><h2>Natera Stock Performance</h2>
<div class="lb-trans"><h2>Natera 股票表現</h2>
</div><p>NTRA traded up $10.83 on Thursday, hitting $213.94. 1,861,579 shares of the company were exchanged, compared to its average volume of 1,650,189. The firm has a fifty day simple moving average of $201.85 and a two-hundred day simple moving average of $215.63. The stock has a market capitalization of $30.64 billion, a PE ratio of -131.25 and a beta of 1.57. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $256.36.</p>
<div class="lb-trans"><p>NTRA 在星期四上漲了 10.83 美元，達到 213.94 美元。該公司交易了 1,861,579 股，相較於其平均交易量 1,650,189 股。該公司的 50 日簡單移動平均為 201.85 美元，200 日簡單移動平均為 215.63 美元。該股票的市值為 306.4 億美元，市盈率為-131.25，貝塔值為 1.57。Natera, Inc.的 12 個月低點為 131.81 美元，12 個月高點為 256.36 美元。</p>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 因遺傳癌症檢測而股價飆升</li>
</ul>
</div><p>Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same quarter in the previous year, the company posted ($0.41) earnings per share. On average, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.</p>
<div class="lb-trans"><p>Natera（納斯達克代碼：NTRA - 獲取免費報告）最後一次公佈季度財報是在 2 月 26 日（星期四）。該醫療研究公司報告每股收益為 0.35 美元，超出市場共識預期的-0.46 美元，超出幅度為 0.81 美元。該公司在本季度的收入為 6.655 億美元，而市場共識預期為 6.0068 億美元。Natera 的股本回報率為-14.74%，淨利潤率為-9.05%。在去年同期，該公司每股收益為-0.41 美元。分析師平均預計 Natera, Inc.在當前年度的每股收益為-1.49 美元。</p>
</div><h2>Institutional Investors Weigh In On Natera</h2>
<div class="lb-trans"><h2>機構投資者對 Natera 的看法</h2>
</div><p>A number of large investors have recently modified their holdings of the stock. Reflection Asset Management bought a new stake in Natera during the fourth quarter worth about $29,000. Palladiem LLC bought a new stake in Natera during the fourth quarter worth about $31,000. Bank of Jackson Hole Trust boosted its stake in Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock worth $37,000 after acquiring an additional 83 shares in the last quarter. International Assets Investment Management LLC boosted its stake in Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company's stock worth $35,000 after acquiring an additional 97 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new stake in Natera during the fourth quarter worth about $39,000. Institutional investors own 99.90% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投資者最近調整了對該股票的持有。Reflection Asset Management 在第四季度購買了 Natera 的新股份，價值約 29,000 美元。Palladiem LLC 在第四季度購買了 Natera 的新股份，價值約 31,000 美元。Jackson Hole Trust 在第四季度將其在 Natera 的持股增加了 103.8%。Jackson Hole Trust 現在擁有 163 股該醫療研究公司的股票，價值 37,000 美元，此前在上個季度又購買了 83 股。International Assets Investment Management LLC 在第一季度將其在 Natera 的持股增加了 132.9%。International Assets Investment Management LLC 現在擁有 170 股該醫療研究公司的股票，價值 35,000 美元，此前在上個季度又購買了 97 股。最後，Kemnay Advisory Services Inc.在第四季度購買了 Natera 的新股份，價值約 39,000 美元。機構投資者持有該公司 99.90% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>NTRA has been the subject of a number of recent analyst reports. Morgan Stanley lowered their price target on shares of Natera from $265.00 to $250.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, March 3rd. JPMorgan Chase &amp; Co. raised their price target on shares of Natera from $260.00 to $265.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, May 8th. Wells Fargo &amp; Company boosted their price objective on shares of Natera from $215.00 to $220.00 and gave the company an &#34;equal weight&#34; rating in a research report on Friday, May 8th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Natera in a research note on Tuesday, April 21st. Finally, Robert W. Baird set a $265.00 target price on shares of Natera in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $256.60.</p>
<div class="lb-trans"><p>NTRA 最近受到了一些分析師報告的關注。摩根士丹利在 3 月 3 日的報告中將 Natera 的目標股價從 265.00 美元下調至 250.00 美元，並對該公司給予 “增持” 評級。摩根大通在 5 月 8 日的報告中將 Natera 的目標股價從 260.00 美元上調至 265.00 美元，並給予該股票 “增持” 評級。富國銀行在 5 月 8 日的研究報告中將 Natera 的目標價從 215.00 美元上調至 220.00 美元，並給予該公司 “持平” 評級。Weiss Ratings 在 4 月 21 日的研究報告中重申了對 Natera 的 “賣出（d-）” 評級。最後，Robert W. Baird 在 5 月 8 日的報告中將 Natera 的目標價設定為 265.00 美元。一位分析師對該股票給予了強烈買入評級，十四位給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，共識目標價為 256.60 美元。</p>
</div><p><strong>View Our Latest Analysis on NTRA</strong></p>
<div class="lb-trans"><p><strong>查看我們對 NTRA 的最新分析</strong></p>
</div><h2>About Natera</h2>
<div class="lb-trans"><h2>關於 Natera</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.</p>
<div class="lb-trans"><p>Natera 是一家全球診斷公司，開發和商業化無細胞 DNA 及其他基因檢測技術用於臨牀應用。該公司專注於三個主要領域：生殖健康（包括無創產前檢測和攜帶者篩查）、腫瘤學（用於最小殘留病和復發監測的腫瘤信息檢測）以及器官移植（用於檢測移植物損傷的無細胞 DNA 檢測）。Natera 結合實驗室檢測、專有生物信息學和臨牀報告，為臨牀醫生和患者提供個性化的基因信息。</p>
</div><p>Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.</p>
<div class="lb-trans"><p>主要產品包括 Panorama，一種無創產前檢測，用於篩查胎兒染色體異常和特定單基因疾病；Horizon 攜帶者篩查，用於遺傳疾病；Signatera，一種個性化的腫瘤信息檢測，用於檢測最小殘留病和監測癌症患者的治療反應；以及 Prospera，一種供體來源的無細胞 DNA 檢測，用於評估器官排斥的風險。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Natera</li>
<li>3 Stocks Rallying on Micron's Price Boost: Substance or Hype?</li>
<li>Snowflake and the Snowballing Impact of its AI Flywheel</li>
<li>AI’s Biggest Bottleneck Could Make These 2 Stocks Soar</li>
<li>These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Natera 更好</li>
<li>3 只因美光價格上漲而上漲的股票：實質還是炒作？</li>
<li>Snowflake 及其 AI 飛輪的滾雪球效應</li>
<li>AI 的最大瓶頸可能使這兩隻股票飆升</li>
<li>這三隻被打壓的股票剛剛看到 2500 萬美元的內部購買</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=NTRA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Natera Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Natera 嗎？</h2>
</div><p>Before you consider Natera, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Natera 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Natera 並不在名單上。</p>
</div><p>While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Natera 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

John Fesko Sells 1,438 Shares of Natera (NASDAQ:NTRA) Stock

Market Beat

Natera

萬基遺傳

摩根士丹利

摩根大通

富國銀行

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

John Fesko 出售了 1,438 股 Natera（納斯達克代碼：NTRA）的股票